Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 95

1.

Use of low-dose tacrolimus and associated hypomagnesemia in the prevention of erectile dysfunction following prostatectomy for prostate cancer.

First MR, Henning AK, Fitzsimmons WE.

Pharmacol Rep. 2016 Jul 30;68(6):1154-1158. doi: 10.1016/j.pharep.2016.07.009. [Epub ahead of print]

PMID:
27607363
2.

The Mutational Robustness of Influenza A Virus.

Visher E, Whitefield SE, McCrone JT, Fitzsimmons W, Lauring AS.

PLoS Pathog. 2016 Aug 29;12(8):e1005856. doi: 10.1371/journal.ppat.1005856. eCollection 2016 Aug.

3.

Pharmacokinetics of prolonged-release tacrolimus and implications for use in solid organ transplant recipients.

Tanzi MG, Undre N, Keirns J, Fitzsimmons WE, Brown M, First MR.

Clin Transplant. 2016 Aug;30(8):901-11. doi: 10.1111/ctr.12763. Epub 2016 Jun 18.

PMID:
27220013
4.

New-Onset Diabetes After Transplantation: Results From a Double-Blind Early Corticosteroid Withdrawal Trial.

Pirsch JD, Henning AK, First MR, Fitzsimmons W, Gaber AO, Reisfield R, Shihab F, Woodle ES.

Am J Transplant. 2015 Jul;15(7):1982-90. doi: 10.1111/ajt.13247. Epub 2015 Apr 16.

5.

Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients.

Silva HT Jr, Yang HC, Meier-Kriesche HU, Croy R, Holman J, Fitzsimmons WE, First MR.

Transplantation. 2014 Mar 27;97(6):636-41. doi: 10.1097/01.TP.0000437669.93963.8E.

6.

New-onset diabetes after transplantation (NODAT): an evaluation of definitions in clinical trials.

First MR, Dhadda S, Croy R, Holman J, Fitzsimmons WE.

Transplantation. 2013 Jul 15;96(1):58-64. doi: 10.1097/TP.0b013e318293fcf8.

PMID:
23619735
7.

Acute rejection characteristics from a prospective, randomized, double-blind, placebo-controlled multicenter trial of early corticosteroid withdrawal.

Gaber AO, Moore LW, Alloway RR, Woodle ES, Pirsch J, Shihab F, Henning A, Fitzsimmons W, Holman J, Reisfield R, First MR; Astellas Corticosteroid Withdrawal Study Group.

Transplantation. 2013 Feb 27;95(4):573-9. doi: 10.1097/TP.0b013e3182777efb.

PMID:
23423269
8.

Effect of corticosteroid withdrawal on tacrolimus and mycophenolate mofetil exposure in a randomized multicenter study.

Shihab FS, Lee ST, Smith LD, Woodle ES, Pirsch JD, Gaber AO, Henning AK, Reisfield R, Fitzsimmons W, Holman J; M. R. First for the Astellas Corticosteroid Withdrawal Group.

Am J Transplant. 2013 Feb;13(2):474-84. doi: 10.1111/j.1600-6143.2012.04327.x. Epub 2012 Nov 21.

9.

Assessment of efficacy and safety of FK778 in comparison with standard care in renal transplant recipients with untreated BK nephropathy.

Guasch A, Roy-Chaudhury P, Woodle ES, Fitzsimmons W, Holman J, First MR; FK778 BK Nephropathy Study Group.

Transplantation. 2010 Oct 27;90(8):891-7. doi: 10.1097/TP.0b013e3181f2c94b.

PMID:
20811320
10.

A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy.

Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P; Astellas Corticosteroid Withdrawal Study Group.

Ann Surg. 2008 Oct;248(4):564-77. doi: 10.1097/SLA.0b013e318187d1da.

PMID:
18936569
11.

Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-month results of the CRAF Study.

Shihab FS, Waid TH, Conti DJ, Yang H, Holman MJ, Mulloy LC, Henning AK, Holman J Jr, First MR; CRAF Study Group.

Transplantation. 2008 May 15;85(9):1261-9. doi: 10.1097/TP.0b013e31816b4388.

PMID:
18475181
12.

Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients.

Alloway R, Steinberg S, Khalil K, Gourishankar S, Miller J, Norman D, Hariharan S, Pirsch J, Matas A, Zaltzman J, Wisemandle K, Fitzsimmons W, First MR.

Transplantation. 2007 Jun 27;83(12):1648-51.

PMID:
17589351
13.

Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients.

Florman S, Alloway R, Kalayoglu M, Punch J, Bak T, Melancon J, Klintmalm G, Busque S, Charlton M, Lake J, Dhadda S, Wisemandle K, Wirth M, Fitzsimmons W, Holman J, First MR.

Transplantation. 2007 Jun 27;83(12):1639-42.

PMID:
17589349
14.

Once-daily tacrolimus extended-release formulation: 1-year post-conversion in stable pediatric liver transplant recipients.

Heffron TG, Pescovitz MD, Florman S, Kalayoglu M, Emre S, Smallwood G, Wisemandle K, Anania C, Dhadda S, Sawamoto T, Keirns J, Fitzsimmons W, First MR.

Am J Transplant. 2007 Jun;7(6):1609-15.

15.

One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients.

Silva HT Jr, Yang HC, Abouljoud M, Kuo PC, Wisemandle K, Bhattacharya P, Dhadda S, Holman J, Fitzsimmons W, First MR.

Am J Transplant. 2007 Mar;7(3):595-608. Epub 2007 Jan 11. Erratum in: Am J Transplant. 2007 Jun;7(6):1682.

16.

Multicenter retrospective analysis of cardiovascular risk factors affecting long-term outcome of de novo cardiac transplant recipients.

Kobashigawa JA, Starling RC, Mehra MR, Kormos RL, Bhat G, Barr ML, Sigouin CS, Kolesar J, Fitzsimmons W.

J Heart Lung Transplant. 2006 Sep;25(9):1063-9. Epub 2006 Jul 18.

PMID:
16962467
17.

Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report.

Kobashigawa JA, Miller LW, Russell SD, Ewald GA, Zucker MJ, Goldberg LR, Eisen HJ, Salm K, Tolzman D, Gao J, Fitzsimmons W, First R; Study Investigators.

Am J Transplant. 2006 Jun;6(6):1377-86.

18.

Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen.

Florman S, Alloway R, Kalayoglu M, Lake K, Bak T, Klein A, Klintmalm G, Busque S, Brandenhagen D, Lake J, Wisemandle K, Fitzsimmons W, First MR.

Transplant Proc. 2005 Mar;37(2):1211-3.

PMID:
15848672
19.

Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen.

Alloway R, Steinberg S, Khalil K, Gourishankar S, Miller J, Norman D, Hariharan S, Pirsch J, Matas A, Zaltzman J, Wisemandle K, Fitzsimmons W, First MR.

Transplant Proc. 2005 Mar;37(2):867-70.

PMID:
15848559
20.

FK778, a synthetic malononitrilamide.

Fitzsimmons WE, First MR.

Yonsei Med J. 2004 Dec 31;45(6):1132-5. Review.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk